Table 1.

Baseline Participant Characteristics and Study Therapy Received

Characteristic			N=17
Age   median (range)				45 (31,57)
Male				17 (100%)
Race/Ethnicity
White, non-Hispanic				8 (47)
Black				4 (24)
Hispanic				3 (18)
Asian/Pacific Islander/Other				2 (12)
KS Disease Characteristics
Oral lesions				1 (6)
≥50 lesions				16 (88)
Tumor-associated edema				16 (88)
Prior treatment for KS*				16 (94)
Cytotoxic Chemotherapy				14 (82)
Local therapies (topical, radiation, or cryotherapy)				4 (24)
Imatinib				4 (24)
Other/experimental therapies				6 (35)
Baseline KSHV Plasma Log-copies/ml, median (IQR)				4.8 (2.5, 5.8)
CD4 T-cell Count, median (range)				489 (133, 1132)
HIV Viral load undetectable				13 (76)
Current Antiretroviral regimens				N =17 (%)
Nucleoside Analog Backbone
ABC/d4T				1 (6)
ABC/3TC/ddI				1 (6)
TDF/FTC or TDF/3TC				12 (71)
3TC				1 (6)
AZT/3TC				1 (6)
Nucleoside-sparing regimen				1 (6)
Non-Nucleoside Agents				6 (35)
EFV				6 (35)
Protease Inhibitors**				10 (59)
Other Classes (raltegravir, maraviroc)				5 (29)
PTC299 Cycles Received	40mg BID	80mg BID	100mg BID	Total
	N=3	N=3	N=11	N=17
median (range)	7 (6,13)	3 (2,5)	4 (1,10)	5 (1,13)

Abbreviations: KS, Kaposi sarcoma; HIV, human immunodeficiency virus; KSHV, Kaposi Sarcoma-associated herpes virus; IQR, interquartile range; ABC, abacavir; d4T, stavudine; 3TC, lamivudine; ddI, didanosine; TDF, tenofovir; FTC, emtricitabine; AZT, zidovodine; EFV, efavirenz.

^*Prior treatments included (# of participants): cytotoxic therapies: liposomal doxorubicin (14), paclitaxel (7), vinblastine (1), etoposide (1), vincristine (1), daunomycin (1); Other/experimental therapies included: valproic acid (2), IM-862 (2), rapamycin (1), flavopiridol (1), Col-3 [incyclinide] (3), interferon-alpha (1), VEGF-antisense (1).

^**Protease inhibitors included were lopinivir/ritonavir, darunavir/ritonavir, and atazanavir with and without ritonavir.